Can-C treatment of age related cataracts in canines.

A Russian research team led by Dr Mark Babizhayev spent nearly a decade testing a variety of anti-glycation agents. Glycation is the result of a sugar molecule like glucose, bonding to a protein or lipid molecule without the controlling action of an enzyme. It is seen as one of the causes of aging and glycation within the eye primarily attributes to a protein build up (debris) concluding in cataract formation. The team understood the role of the anti-glycation, anti-oxidant, L-Carnosine and this knowledge led to the development of n-alpha-acetylcarnosine as the delivery system into the eye for L-carnosine.

N-alpha-acetyl-carnosine (shortened and more commonly now known simply as NAC) began to be tested in the eyes of animals, particularly in canines and rabbits. These studies produced quick and excellent results in the improvement of clarity and overall vision for the animals involved. Additionally there were no side effects and the positive affects were sustainable.

Dr Mark commented that ‘the treatment of age-related cataracts in canines and rabbits has been conducted and the efficacy of using NAC for cataract treatment was established. The striking results in canines and rabbits for both cataract reversal and prevention of lens opacities are clear."

12 years ago NAC eye drops were introduced to the world as IVP approved Can-C. IVP stands for Dr Mark’s organisation Innovative Vision Products.
In a controlled study of 30 dogs with cataracts, a topical application of Can-C (1% NAC) eye drop solution was applied twice daily. The study demonstrated that:
The drops improved visual behaviour of the animals within weeks of treatment.
Cataract reversal starts from the periphery of the cataract followed by increased transparency of the lens.
96% of canine eyes treated with N-acetylcarnosine (Can-C) showed notable improvements.
Dogs with both immature and ripe cataracts showed significant visual improvement.

Can-C.biz have recently discovered that half of their customers are buying their IVP approved Can-C for their dogs. Perhaps they are in agreement with Dr Mark who noted that Can-C appears to work even more effectively in canines than in humans! The dosage for animals has not yet been clearly defined, so most pet owners are following the same dosage recommendation for humans and are applying 3 to 4 drops per affected eye daily. If in doubt, discuss with your veterinarian.

NOTE: Can-C™ is manufactured in a GMP certified, pharmaceutical facility which meets ISO 9001:2000 and ISO 13485:2003 standards for the design/formulation and manufacture of sterile contact lens solution and pharmaceutical solutions.